News & Events

Simpson Thacher is representing J.P. Morgan Securities LLC as financial advisor to Celgene Corporation (NASDAQ: CELG) in a tender offer and merger transaction, pursuant to which Celgene Corporation’s wholly owned subsidiary, Blue Magpie Corporation, will offer to purchase all of the outstanding shares of common stock of Juno Therapeutics, Inc. (NASDAQ: JUNO) at a price of $87.00 per share, for a total of approximately $9 billion, net to the seller in cash, without interest and less required withholding taxes. If successful, the tender offer will be followed by a merger of Blue Magpie Corporation with and into Juno Therapeutics, with Juno Therapeutics surviving the merger as a wholly-owned subsidiary of Celgene Corporation.

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Juno Therapeutics, Inc. is an integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer.

The Simpson Thacher team includes Caroline Gottschalk and Erika Tang (M&A).